Cargando…
A Phase II Study of Cetuximab (Erbitux®) plus FOLFIRI for Irinotecan and Oxaliplatin-refractory Metastatic Colorectal Cancer
We have evaluated the efficacy and safety of cetuximab plus FOLFIRI for irinotecan and oxaliplatin-refractory colorectal cancers. From September 2004 to February 2006, 31 patients with metastatic colorectal cancer were treated with cetuximab (400 mg/m(2) intravenously [IV] over 2 hr on day 1 followe...
Autores principales: | Koo, Dong Hoe, Lee, Jae-Lyun, Kim, Tae Won, Chang, Heung Moon, Ryu, Min-Hee, Lee, Sung Sook, Kim, Min Kyoung, Sym, Sun Jin, Lee, Jung Shin, Kang, Yoon-Koo |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
The Korean Academy of Medical Sciences
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2694394/ https://www.ncbi.nlm.nih.gov/pubmed/17923763 http://dx.doi.org/10.3346/jkms.2007.22.S.S98 |
Ejemplares similares
-
Severe Acneiform Eruption Induced by Cetuximab (Erbitux®)
por: Lee, Jung Eun, et al.
Publicado: (2008) -
A Japanese Post-marketing Surveillance of Cetuximab (Erbitux(®)) in Patients with Metastatic Colorectal Cancer
por: Ishiguro, Megumi, et al.
Publicado: (2012) -
Bevacizumab plus capecitabine as later-line treatment for patients with metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines
por: Bang, Yeong Hak, et al.
Publicado: (2021) -
Cetuximab plus chronomodulated irinotecan, 5-fluorouracil, leucovorin and oxaliplatin as neoadjuvant chemotherapy in colorectal liver metastases: POCHER trial
por: Garufi, C, et al.
Publicado: (2010) -
Combined treatment of adenoid cystic carcinoma with cetuximab and IMRT plus C12 heavy ion boost: ACCEPT [ACC, Erbitux(® )and particle therapy]
por: Jensen, Alexandra D, et al.
Publicado: (2011)